John Desjarlais

Dr John Desjarlais is the Chief Scientific Officer at Xencor, Inc., an LA-area company that specializes in creating antibody therapies that mobilize the immune system against cancer. Dr Desjarlais has been with Xencor since 2001.Dr. Desjarlais oversees all aspects of discovery and research at the company including technology development, protein and antibody engineering and generation of drug candidates. Prior to joining Xencor, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University, where he developed protein engineering methods similar to Xencor’s PDA® technology platform. Dr. Desjarlais received a B.S. in Physics from the University of Massachusetts and a Ph.D. in Biophysics from Johns Hopkins University. He then conducted postdoctoral research at the University of California, Berkeley. Dr. Desjarlais has driven the company’s technology development and engineering efforts for over 5 years and participated in the business development and intellectual property strategies.